Objective: Duchenne muscular dystrophy (DMD) is a severe X-linked recessive disease caused by loss-of-function dystrophin (DMD) mutations in boys, who typically suffer loss of ambulation by age 12. Previously, we reported that coding variants in latent transforming growth factor beta (TGFβ)-binding protein 4 (LTBP4) were associated with reduced TGFβ signaling and prolonged ambulation (p = 1.0 × 10 −3 ) in DMD patients; this result was subsequently replicated by other groups. In this study, we evaluated whether additional DMD modifier genes are observed using whole-genome association in the original cohort. Methods: We performed a genome-wide association study (GWAS) for single-nucleotide polymorphisms (SNPs) influencing loss of ambulation (LOA) in the same cohort of 253 DMD patients used to detect the candidate association with LTBP4 coding variants. Gene expression and chromatin interaction databases were used to fine-map association signals above the threshold for genome-wide significance. Results: Despite the small sample size, two loci associated with prolonged ambulation met genome-wide significance and were tagged by rs2725797 (chr15, p = 6.6 × 10 −9 ) and rs710160 (chr19, p = 4.7 × 10 −8 ). Gene expression and chromatin interaction data indicated that the latter SNP tags regulatory variants of LTBP4, whereas the former SNP tags regulatory variants of thrombospondin-1 (THBS1): an activator of TGFβ signaling by direct binding to LTBP4 and an inhibitor of proangiogenic nitric oxide signaling. Interpretation: Together with previous evidence implicating LTBP4, the THBS1 modifier locus emphasizes the role that common regulatory variants in gene interaction networks can play in mitigating disease progression in muscular dystrophy.
D uchenne muscular dystrophy (DMD [MIM:
310200]) is a severe, progressive muscular dystrophy that affects 1 per 5,000 live male births. 1, 2 The extreme size of the DMD gene (2.2Mb) leads to a range of primary mutations, including mutations that produce reduced amounts of functional dystrophin and result in a milder form of the disease, Becker muscular dystrophy (BMD [MIM: 300376]). Complete loss-of-function DMD mutations disrupt the dystrophin-glycoprotein complex leading to muscle membrane fragility, with eventual muscle tissue loss and replacement by fat and fibrotic tissue. However, even without dystrophin protein, there is variability in clinical progression of disease symptoms, suggesting that genetic background may play a role in modulating the disease process. Consistent with observations of genetic modifiers of muscle disease severity in animal models, 3, 4 several human candidate gene associa-In mouse models of muscular dystrophy, a coding variant in latent transforming growth factor beta (TGFβ) binding protein 4 (Ltbp4) is associated with disease severity, and modifies both muscle membrane permeability and fibrosis. 3 Concordant with mouse Ltbp4, human LTBP4 coding polymorphisms are associated with disease severity in multiple DMD cohorts. 6, 8, 9 Four nonsynonymous LTBP4 singlenucleotide polymorphisms (SNPs; rs2303729, p.Val127Ile; rs1131620, p.Thr720Ala; rs1051303, p.Thr753Ala; and rs10880 p.Thr1074Met; NP_001036010.1) are in moderate linkage disequilibrium (LD), resulting in two major LTBP4 protein coding haplotypes, designated as VTTT (risk) and IAAM (protective) protein isoforms. Both human and mouse protective alleles show reduced TGFβ signaling in fibroblast assays, and the human IAAM isoform displays higher avidity for TGFβ, 10 consistent with LTBP4 controlling the bioavailability of latent TGFβ, thus leading to reduced dystrophic muscle damage. An earlier candidate gene association with osteopontin (SPP1), an extracellular matrix (ECM) protein and proinflammatory cytokine, implicated a SPP1 promoter SNP as a modifier of muscle weakness progression in DMD. 5 
SPP1
gene expression is highly induced in dystrophic muscle, 11, 12 and knockout of Spp1 in the mdx mouse (a stop codon mutation in exon 23 of the Dmd gene) results in a milder muscle phenotype 13 and also shifts infiltrating macrophages to a regenerative phenotype. 14 An analysis that combined both Spp1 ablation and protective Ltbp4 variants in the mouse suggests that they work synergistically to reduce the harmful effects of TGFβ signaling in dystrophic muscle. 15 To detect genome-wide modifiers of disease severity in DMD, we make use of patients enrolled in the United Dystrophinopathy Project (UDP), a multisite consortium established to study genotype-phenotype correlations in DMD, BMD, and related dystrophinopathy patients. [16] [17] [18] Using a candidate gene approach, we previously reported associations in the UDP cohort between coding variants in LTBP4 and age at LOA under a recessive model. 6 Here, we report a genome-wide association analysis in this same cohort, using SNP data that passed quality control for 253 DMD patients for association with LOA, with steroid use and DMD gene mutation type as covariates.
Subjects and Methods

Subjects and Clinical Classification
All subjects have a known DMD mutation confirmed by either MLPA or DNA sequencing and have been previously described. 16 Informed consent was obtained under institutional review boardapproved protocols. Genomic DNA was extracted from venous blood samples and phenotypic data were extracted from clinical records; most subjects underwent prospective clinical examinations as well. Ambulatory loss was defined by full-time wheelchair use (requiring wheelchair within the home) and recorded to the nearest month when available, and otherwise to the nearest half-year of age. All patients in this analysis had ambulatory loss before 20 years of age (LOA mean = 10.6; standard deviation [SD] = 2.3). Glucocorticoid treatment was defined as use of any steroid regimen for more than 6 months that began at least 6 months preceding LOA (137 subjects, mean age at ambulatory loss was 10.9 [±2.3] years). Untreated was defined as never exposed, exposed to any steroid regimen for less than 6 months, or had onset of treatment less than 6 months preceding LOA (101 subjects, mean age at ambulatory loss was 10.0 [±2.1] years). The mutation class assignment was either "truncating" DMD mutations (211 subjects, mean age at ambulatory loss was 10.4 [±2.2] years) or "other" DMD mutations (42 subjects, mean age at ambulatory loss was 11.3 [±2.4] years).
Illumina Array Genotyping and Quality Control
Whole-genome genotyping was performed on archived genomic DNA that had been previously collected for DMD mutation analysis. Human Infinium Omni2.5Exome-8 v1. default parameters with K = 3 on the combined genotypes and, for testing the effect of population stratification, filtered the UDP samples by the minimum ancestry fraction value (=0.967) observed for the CEU population. The phenotype was Age at Loss of Ambulation (LOA), and primary analyses included the covariates Steroid Use and DMD Mutation Class. Data were initially analyzed under a recessive model, which is the model that had previously been established for LTBP4; the genome scan was subsequently repeated under additive and dominant models. Global and haplotype-specific tests for association used the haplo.score routine from the haplo.stats 25 package in R (R Foundation for Statistical Computing, Vienna, Austria). Gene-based rare-variant testing used the optimal Sequence Kernel Association Test
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(SKAT-O) as implemented in the Efficient and Parallelizable Association Container Toolbox EPACTS, using the skat-o small sample adjustment version of the mmskat test. Rare-variant associations included Steroid Use and DMD Mutation Class as covariates and used a linear mixed model (EMMAX) adjustment to account for population structure and relatedness. LTBP4 haplotypes were estimated from unphased genotype data and evaluated for association with age of ambulatory loss as a quantitative trait or RNA sequencing (RNA-seq) transcripts per million (TPM) values for LTBP4 expression levels in macrophages. Regional linkage disequilibrium plots were generated with LocusZoom. 27 
Genotype-Tissue Expression and Chromatin Interaction Data
The GTEx portal (GTEx Analysis Release V6p, dbGaP Accession phs000424.v6.p1, https://www.gtexportal.org) was used to access precalculated eQTL statistics for chromosome 15 SNPs and thrombospondin-1 mRNA expression (THBS1, ENSG00000137801) in skeletal muscle (gastrocnemius) tissue, and sample-level box plots of rank normalized gene expression. LTBP4 expression data (ENSG00000090006) in macrophages were obtained from the NBCI GEO data (GEO accession number GSE81046, processed data file with gene-level TPM values downloaded from GSE81046_RAW.tar). Sample-level genotype data for GSE81046 were provided by Dr. Luis B. Barreiro, CHU Sainte-Justine/University of Montreal. 28 UCSC genome browser BED Files of enhancers from human skeletal muscle myotubes were retrieved from Data S2 zipped file from Hinsz et al. 29 Additional chromatin analysis tracks that were retrieved from the UCSC Genome Browser (Human Feb. 2009, GRCh37/hg19 Assembly) included: Human Skeletal Muscle Myoblasts (HSMM) Chromatin State Segmentation by HMM from ENCODE/Broad, Transcription Factor ChIP-seq Uniform Peaks from ENCODE/Broad/Analysis for CTCF in Human Skeletal Muscle Myotubes, Transcription Factor ChIP-seq (CTCF) from ENCODE with Factorbook Motifs, and DNaseI Hypersensitivity Clusters in 125 cell types from ENCODE (V3). The Promoter Capture Hi-C (PCHi-C) peak matrix file from 17 human primary hematopoietic cell types, consisting of CHiCAGO scores for all interactions that pass a cutoff of >=5 in at least one cell type, were downloaded from the from the Open Science Framework repository (accession u8tzp). 30 
Results
Identification of Genome-Wide Significant Variants
Previous candidate gene studies in DMD cohorts using age at LOA as the phenotype reveal nonadditive intralocus effects of the modifier SNPs. LTBP4 SNPs/haplotypes show greater protective effects with a recessive model, 6, 8, 9 whereas SPP1 and CD40 SNPs show greater risk effects with a dominant model 5, 7 ; therefore, we performed an initial GWAS for all three (recessive, additive, and dominant) genetic models. Three SNPs tagging two loci exceeded a conventional genome-wide significance threshold of p value ≤ 5 × 10 −8 (−log 10 [p value] ≥ 7.3): rs2725797
and rs2624259 at 15q14 (r 2 = 0.95), and rs710160 at 19q13.2 (Fig 1; Table 1 ) using the previously supported recessive model for age at loss of ambulation. 6, 8, 9 Under additive and dominant models, no single locus exceeded a genome-wide significance threshold, although rs2624259 and rs2725797 at 15q14 remained among the top 15 associated loci (p = 7.5 × 10
) under an additive model (Table S1 ). Quantile-quantile plots of the p-value distributions indicated little systematic bias and estimation of ancestry using principal component analysis or modelbased estimation showed that the 253 UDP subjects have predominantly European genetic ancestry (Fig S1) . After removing 10 subjects classified as ancestral outliers by principal component analysis, the top three SNPs remained within the top 10 genome-wide signals (N = 243; Table 1 ). A more stringent filter for population stratification required European ancestry equivalent to the CEU reference population (Utah residents with ancestry from northern and western European ancestry), and after removing an additional 54 subjects, the association of rs2725797, rs2624259, and rs710160 with LOA remained robust (N = 189; Table 1 ). All SNP results with a nominal −log 10 [p value] > 2.0 in both the N = 253 and (Fig 1C) , but the D' statistics suggested rs710160 alleles were unevenly distributed between VTTT/IAAM haplotypes. Phased haplotypes were estimated from the 253 DMD subjects and showed that the rs710160_C allele subdivided the IAAM haplotype (Fig 2A) . (Table 2 ), the C-IAAM haplotype was the most protective (p = 2 × 10 −5 ).
Next, we investigated the relationship of regional SNPs with LTBP4 transcript levels by querying expression quantitative trait locus (eQTL) databases. In monocytederived macrophages collected from 91 EuropeanAmericans (EA) and 77 African-Americans (AA), 66 SNPs in the LTBP4 region, including rs710160 and the four coding SNPs (rs2303729, rs1131620, rs1051303, and rs10880), were nominally associated with LTBP4 transcript levels, with 32 LTBP4 eQTL associations having an estimated genome-wide false discovery rate <1% in macrophages. 28 We reanalyzed these LTBP4 eQTLs in the 91 EA subjects and observed that minor alleles of rs710160 and the individual VTTT/IAAM SNPs were associated with lower LTBP4 transcript levels in macrophages (Fig 2B) . When haplotype-specific tests for expression levels were examined (Table 2 ), the C-IAAM haplotype associated with lower LTBP4 transcript levels (p = 0.004), T-IAAM was not significantly associated (p = 0.38), and T-VTTT associated with higher transcript levels (p = 0.0003). Additionally, we searched for rs710160 eQTLs in 43 tissues and cell lines collected by the Genotype-Tissue Expression (GTEx) Project and observed that the top rs710160 association with LTBP4 expression was in transformed fibroblasts (272 subjects: p = 0.00039, β = -0.13, standard error [SE] = 0.037), where the C allele was also associated with lower LTBP4 transcript levels (Fig 2C) .
Long-Range Chromatin Interactions Link rs2725797 to the Thrombospondin-1 Promoter
We next imputed SNPs in the chromosome 15q14 region tagged by the genome-wide significant SNPs (rs2725797 and rs2624259) and observed a strong LD block (r 2 > 0.8) comprising 48 SNPs located between chr15:
39,055,584-39,110,903 (Fig 1B) . This LD block is in a large gene desert; however, the thrombospondin-1 gene (THBS1) is located 750kb telomeric from rs2624259. Thrombospondin-1 (TSP-1; encoded by the THBS1 gene) is a major activator of TGFβ signaling and directly interacts with LTBP4 in the ECM. 31, 32 Because THBS1 expression is elevated in mdx mice, 33 we examined the region between the rs2725797-tagged LD block and the THBS1 gene for features that regulate gene expression. We searched for evidence of long-range chromatin interactions between the rs2725797-tagged LD block and the THBS1 promoter using chromosome conformation capture data, specifically with promoter capture Hi-C (PCHi-C) data from 17 human primary blood cell types. 30 The 3.7-kb HindIII fragment containing the THBS1 promoter (chr15:39872009-39875707) pulls down 142 flanking HindIII fragments with high confidence (Capture Hi-C Analysis of Genomic Organization "CHiCAGO" interaction score ≥ 5 in at least one cell type) and the genomic locations of these promoter-interacting fragments are shown as arcs connecting the captured HindIII fragments to the THBS1 promoter (Fig 3) . We sorted the 142 captured HindIII fragments by their median THBS1 promoter interaction score across all 17 cell types and observed that the two highest scoring fragments contained the two top SNPs associated with LOA (rs2725797 in 1.1-kb fragment E chr15:39108568-39109689, median score = 17.6; rs2624259 in 11.0-kb fragment F chr15:39109690-39120732, median score = 10.6).
rs2725797 and rs2624259 Flank a Strong Enhancer Feature and CTCF Binding Site RNA-seq data showed that THBS1 is highly expressed in pediatric skeletal muscle, and features associated with transcriptionally active regulatory elements are found throughout the region between the rs2725797-tagged LD block and THBS1 in human skeletal muscle myotubes (HSMMs), including stretch enhancers and chromatin marks for histone H3 acetylated at lysine 27 (H3K27ac) and CCCTC-binding factor (CTCF) sites from ChIP-Seq data (Fig 3) . A prominent CCCTC-binding factor (CTCF) binding site, which mediates long-range interactions between distant enhancers and their promoters, is observed between rs2725797 and rs2624259, in HSMMs and in multiple cell types. A DNase I hypersensitive site, indicative of open chromatin and a cis-regulatory element, is observed in this same location in 122 of 125 cell types, suggesting that this region binds regulatory/modulatory proteins in a broad range of cell types.
rs2725797 Is Associated With Reduced THBS1 Messenger RNA Expression in Skeletal Muscle Given the density of regulatory features in the vicinity of rs2725797, we searched for THBS1 eQTLs in 43 tissues and cell lines collected by the GTEx Project and observed that the top rs2725797:THBS1 eQTL association was observed in skeletal muscle tissue (361 subjects: p = 0.0049, β = -0.18, SE = 0.063). SNPs in strong LD with rs2725797, including rs2624259, were also associated with THBS1 expression in skeletal muscle (Fig 4A) , and the minor allele (protective for LOA) was also associated with lower expression. The pattern of SNP association signals for THBS1 skeletal muscle expression and LOA were comparable when SNPs in the entire rs2725797 LD block were examined (Fig 4B) . Finally, when 1,569 SNPs from 923kb upstream to 20kb downstream of the THBS1 promoter were ranked by their THBS1 skeletal muscle eQTL statistic, 64 SNPs in strong LD with rs2725797 (r 2 > 0.6) ranked in the top 72 (including 58 of the top 59) regional THBS1 ciseQTLs.
Joint LTBP4 and THBS1 Variant Effects on LOA
It is noteworthy that LTBP4 and THBS1 encode directly interacting proteins that control TGFβ bioavailability, and that the longest ambulating DMD patient in our cohort (LOA at age 18) was homozygous for protective alleles at both loci. We therefore partitioned the 253 DMD patients by their number of LTBP4 and THBS1 alleles, and the joint effect of protective THBS1 alleles and a homozygous rs710160 protective genotype resulted in an average delay in LOA of 1.2, 3.5, and 6.8 years for 0, 1, or 2 protective THBS1 rs2725797 alleles (Fig 5A) , respectively.
Discussion
We have found evidence that regulatory variants associated with reduced expression of LTBP4 and THBS1 prolong ambulation in this cohort of DMD patients. Functional enhancer SNPs have been major candidates for causal variants underlying GWAS loci, and the availability of functional high throughput data from the ENCODE 34 and GTEx 35 projects were critical to interpreting the functional role of the THBS1 enhancer SNPs. These DMD modifier loci are an example of common regulatory variants typically found by GWAS having a role in the phenotypic variability of a rare Mendelian disease. The genomewide association strengthened and refined the known LTBP4 IAAM association with prolonged ambulation. Fine-mapping of regulatory variants in linkage disequilibrium with the IAAM coding SNPs suggests that the most protective human LTBP4 haplotype combines reduced messenger RNA (mRNA) expression with tighter latent TGFβ binding, as has been demonstrated for the IAAM protein isoform. 10 When transgenic human LTBP4
VTTT protein isoform is overexpressed in the mdx model, muscle disease is aggravated 36 and sarcolemmal damage of dystrophic muscle fibers is increased. 37 The combination of reduced expression and the LTBP4 IAAM protein isoform known to have less TGFβ release is consistent with mouse models where reduced latent TGFβ bioavailability lessens disease progression in the injured myofiber. TSP-1 is a multifunctional, ECM glycoprotein that is both an activator of TGFβ signaling 32, 38 and an antiangiogenic factor. 39, 40 The protective effect of the THBS1 distal regulatory SNPs may be exerted through multiple distinct TSP-1 functions (Fig 5B) . LTBP4 sequesters latent TGFβ complex in the ECM through a disulfide linked latency-associated peptide (LAP) and TSP-1 activates ECM-bound latent TGFβ 38 by direct interaction with LAP. 32 TSP1-null mice have similar histological abnormalities as observed in TGF-β1 null mice, and TSP1-null fibroblasts produce only 15% of the amount of active TGF-β1 as wild-type fibroblasts. 38 Upregulation of TSP-1 expression by angiotensin-II-mediated signaling leads to TGFβ activation in both cardiac fibroblasts 41 and human mesangial cells. 42 In the diaphragm of dystrophin-deficient mdx mice, TSP-1 expression is elevated and administration of the angiotensin-II type 1 receptor blocker losartan decreases TSP-1 expression and reduces excessive TGFβ signaling. 33 In the dysferlin-deficient mouse model of limb-girdle muscular dystrophy type 2B, TSP-1 accumulates at high levels in skeletal muscle and is correlated with both inflammatory activity and disease progression. 43, 44 Differentiation in primary cell cultures of myotubes from dysferlin-deficient myoblasts results in upregulation of THBS1 mRNA, 45 indicating active regulation of THBS1 transcription in muscle cells. The location of SNPs associated with LOA within the strongest enhancer-THBS1 promoter chromatin contact across multiple cell types suggests that these enhancer variants may exert their protective effect by altering the regulation of THBS1 transcription in the injured myofiber, thus reducing TGFβ activation.
TSP-1 also has direct effects on inhibiting angiogenesis through CD36-and CD47-mediated suppression of nitric oxide (NO) signaling and by modulating the activity and bioavailability of vascular endothelial cell growth factor (VEGF). 40 Activation of the CD47 receptor by TSP-1 binding leads to downstream inhibition of proangiogenic NO/cGMP (cyclic guanosine monophosphate) signaling.
Reduced angiogenesis by a VEGFA-dependent pathway leads to impaired regeneration of skeletal muscle fibers in mdx mice, 46 and an increased vascular density in skeletal muscle is associated with reduced dystrophic pathology, as observed in mdx mice crossed to a heterozygous knockout of VEGF receptor-1 (mdx:Flt-1 +/− ). 47 TSP-1 null mice also have increased capillary density in skeletal and cardiac muscle. 48 Thus, a second mechanism for the protective effects of THBS1 regulatory SNPs may be to decrease TSP-1 levels, which promotes a proangiogenic response in dystrophic muscle by modulating the VEGF pathway. The LTBP4 and THBS1 regulatory SNPs reported here join additional examples of expression levels ameliorating the DMD phenotype, including Jagged1 overexpression in the golden retriever muscular dystrophy model, and in humans, rs28357094 in the SPP1 promoter 5 and rs1883832 in the CD40 Kozak consensus sequence. 7 As in previous candidate modifier gene studies with LOA in human DMD cohorts, these new associations show nonadditive (recessive) protective effects of the modifier variants on the expressivity of DMD mutations. Whether this is a general observation for DMD modifiers will require additional examples; however, we suggest that recessivity in this case may arise from protein-protein and pathway interactions involving LTBP4 and TSP-1 that jointly perturb the physiological robustness of the TGFβ pathway. A limitation of this study is the small sample size, although it remains one of the largest LOA genetic cohorts reported. These results warrant replication in additional cohorts, but we note that this sample was adequate to identify a protective effect of the LTBP4 gene, a finding that has subsequently been confirmed in additional cohorts. 8, 9 Previous candidate associations have supported SPP1
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, LTBP4, 8, 9 and CD40 7 as modifiers of DMD, but, to our knowledge, this is the first study to identify genome-wide significant modifiers. That genome-wide significant noncoding variants in two interacting genes were identified in just 253 patients suggests that larger cohorts will uncover additional modifiers. Identification of such protective modifiers is important, given that they provide additional pathways for therapeutic intervention in DMD, which will be independent of mutation class and complementary to dystrophin restorative therapies. 
